rare diseases

Biotech revenue plans ‘won’t look as sunny’ after Trump tax bill

Insurance coverage losses caused by the tax and spend law could make it harder for biotechs to seek funding and recruit patients, experts told Fierce.

Will Maddox Jul 9, 2026 9:28am

Fierce Pharma

Vertex to pay $10B for Crinetics in its largest-ever deal

Jul 7, 2026 8:08am

Praxis faces FDA delay, analysts point finger at agency layoffs

Jun 30, 2026 4:13am

BioCryst ends internal programs in pivot to partnerships

Jun 29, 2026 10:30am

AstraZeneca posts phase 3 bone disease data on Strensiq heir

Jun 29, 2026 4:51am

Brain and money connected by a thread on a white background

Ionis bags $30M from Recordati for ex-US rare disease rights

Jun 25, 2026 6:59am